The Dayton Clinical Oncology Program (DCOP) was incorporated in the State of Ohio in 1982 as a non-profit 501 C-3 corporation. A Consortium Agreement was established between DCOP, the Dayton Area hospitals (all except Children's Medical Center), and Wright State University (WSU). A governing board was established, and corporate bylaws were developed. Currently, DCOP has an elected Board of Trustees with Howard M. Gross, M.D., DCOP Principal Investigator, as Chairperson of the Board, Stuart Merl, M.D., Associate Principal Investigator, as Vice Chairperson, Sidney J. Pinkus, MBA, Chief Executive Officer of DCOP, as President of the Board, and 15 other Trustees representing the 13 member hospitals, WSU, and at-large community members of our service area. The Board meets quarterly to review budget reports and program activities. Since 1982, DCOP has successfully applied for and received funding from NCI as a CCOP. We are currently seeking continued funding through the fiscal year ending May 31, 2014. Our current staff includes 16 Oncology Research Nurses funded by our member hospitals, and 16 office staff funded by the grant, including directors for quality, regulatory, and prevention, quality coordinator, data coordinator, research manager, data managers, administrative assistant, research associates, and research coordinators. Our current active physician Co Investigators total 74, representing our 13 hospitals and various specialties including oncology, radiation therapy, urology, surgery, gynecology, pulmonary and gastroenterology. WSU has been providing personnel, payroll, and accounting services support through a sub-contracting relationship established on December 23, 2001, when the grant was transferred from former fiscal agent Kettering Medical Center to DCOP. DCOP has continued as the grantee organization since that date.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dayton Clinical Oncology Program
United States
Zip Code
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9

Showing the most recent 10 out of 165 publications